Genetic Technologies Limited (GNTLF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Genetic Technologies Limited (GNTLF) trades at $1.00 with AI Score 44/100 (Grade C). Genetic Technologies Limited (GNTLF) is an Australian molecular diagnostics company focused on predictive genetic testing, particularly for women's health. Market cap: $1.34B, Sector: Healthcare.
Price live · AI analysis from Jun 14, 2026Analyst Coverage for GNTLF: GNTLF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates GNTLF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
GNTLF: the 1 perspectives are evenly split.
How is this calculated? →Genetic Technologies Limited (GNTLF) Healthcare & Pipeline Overview
Genetic Technologies Limited (GNTLF) specializes in advanced molecular diagnostics, particularly in women's health, offering innovative genetic risk assessment tools that support healthcare professionals in Australia and the United States.
What Is the Investment Thesis for GNTLF?
Genetic Technologies Limited (GNTLF) presents a compelling investment thesis driven by its innovative product offerings and strategic partnerships. The company's flagship product, BREVAGenplus, has established itself as a critical tool in breast cancer risk assessment, targeting a significant market in women's health. The growing emphasis on personalized medicine and preventative healthcare is expected to drive demand for Genetic Technologies' risk assessment tools, particularly as the global molecular diagnostics market is projected to grow at a CAGR of 10.9% from 2021 to 2028. Additionally, ongoing development efforts for new diagnostics targeting various health conditions, including cardiovascular disease and type 2 diabetes, could further enhance revenue streams. However, investors should remain cautious of the company's current financial metrics, including a profit margin of -156.8%, which indicates ongoing challenges in achieving profitability. The market capitalization of $1.34B reflects the company's potential, but liquidity and volatility risks associated with its OTC trading status warrant careful consideration.
Based on FMP financials and quantitative analysis
GNTLF Key Highlights
- Market Cap of $1.34B indicates a significant presence in the molecular diagnostics sector.
- Gross Margin of 50.9% showcases the company's ability to maintain profitability on its products.
- Profit Margin of -156.8% highlights ongoing challenges in achieving profitability.
- Beta of 0.17 suggests lower volatility compared to the broader market, indicating stability.
- No dividend yield reflects the company's focus on reinvesting in growth opportunities.
Who Are GNTLF's Competitors?
GNTLF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| NTRA Natera, Inc. | $283.80 | +1.60% | $40.64B | 35 |
| EXAS Exact Sciences Corporation | $104.91 | +0.00% | $20.03B | 62 |
| MYGN Myriad Genetics, Inc. | $6.19 | +3.31% | $584.48M | — |
| PRE Prenetics Global Limited | $17.25 | +1.88% | $293.23M | 69 |
| EPGNY Epigenomics AG | $2.39 | +0.00% | 68 | |
| STRRP Star Equity Holdings, Inc. | $9.89 | -0.10% | $40.58M | 68 |
| TWST Twist Bioscience Corporation | $100.97 | +1.74% | $6.29B | 65 |
| CNTG Centogene N.V. | $0.33 | +100.00% | $9.42M | 50 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are GNTLF's Key Strengths?
- Innovative product offerings in predictive genetic testing.
- Strong partnerships with leading research institutions.
- Established market presence in Australia and growing interest in the U.S.
What Are GNTLF's Weaknesses?
- Current negative profit margin indicating financial challenges.
- Limited brand recognition compared to larger competitors.
- Dependence on a small number of key products for revenue.
What Could Drive GNTLF Stock Higher?
- Expansion of BREVAGenplus into new healthcare markets.
- Development of new diagnostic tools targeting various health conditions.
- Strategic partnerships with U.S.-based healthcare providers to enhance market reach.
What Are the Key Risks for GNTLF?
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Intense competition from established players in the molecular diagnostics sector.
- Regulatory challenges impacting product development and market entry.
- Market volatility and liquidity risks associated with OTC trading.
What Are the Growth Opportunities for GNTLF?
- Expansion of BREVAGenplus: The flagship product BREVAGenplus targets a growing market for breast cancer risk assessment. With breast cancer being one of the most common cancers among women, the demand for effective risk evaluation tools is increasing. The global breast cancer diagnostics market is projected to grow at a CAGR of 7.3% from 2022 to 2028, providing a significant opportunity for Genetic Technologies to expand its market share and enhance revenue through increased adoption of BREVAGenplus.
- Development of New Diagnostic Tools: Genetic Technologies is actively developing new risk assessment diagnostics for various conditions, including cardiovascular disease and type 2 diabetes. As the global market for cardiovascular diagnostics is expected to reach $20 billion by 2025, the introduction of innovative tools in this space could diversify the company's product offerings and tap into new revenue streams.
- Geographic Expansion into the U.S. Market: With a strong presence in Australia, Genetic Technologies has the opportunity to expand its operations into the U.S. healthcare market, which is the largest in the world. The U.S. molecular diagnostics market is projected to grow significantly, and by establishing partnerships with U.S.-based healthcare providers, Genetic Technologies could enhance its reach and impact in women's health diagnostics.
- Collaboration with Research Institutions: The company's ongoing collaborations with leading research institutions, such as the University of Melbourne and Memorial Sloan Kettering, present opportunities for innovation and development of cutting-edge diagnostic tools. These partnerships can accelerate research and development efforts, leading to the introduction of new products and services that meet evolving healthcare needs.
- Increasing Demand for Genetic Testing Services: The growing awareness and acceptance of genetic testing in healthcare present a substantial opportunity for Genetic Technologies. With an increasing focus on preventative healthcare and personalized medicine, the demand for genetic testing services across various applications, including medical, forensic, and botanical, is expected to rise, providing a broader market for the company's offerings.
What Opportunities Does GNTLF Have?
- Expansion into the U.S. market presents significant growth potential.
- Increasing demand for personalized medicine and preventative healthcare.
- Development of new diagnostic tools targeting various health conditions.
What Threats Does GNTLF Face?
- Intense competition from established players in the diagnostics sector.
- Regulatory challenges in the healthcare industry.
- Market volatility and liquidity risks associated with OTC trading.
What Are GNTLF's Competitive Advantages?
- Strong focus on women's health provides a unique market position.
- Established relationships with leading healthcare professionals and institutions.
- Innovative product offerings that address specific healthcare needs.
- Ongoing research and development efforts to stay ahead of industry trends.
- Expertise in genetic testing across multiple applications enhances credibility.
What Does GNTLF Do?
Genetic Technologies Limited, established in 1987 and headquartered in Fitzroy, Australia, is a pioneering molecular diagnostics enterprise focused on delivering advanced predictive assessment instruments. The company primarily aims to assist medical professionals in managing women's health through its flagship product, BREVAGenplus, a rigorously validated risk evaluation test for non-inherited breast cancer. Genetic Technologies promotes BREVAGenplus to a diverse range of healthcare specialists, including breast health clinics, imaging centers, obstetricians/gynecologists, and breast cancer risk analysts. In addition to BREVAGenplus, the company offers a suite of cancer risk assessment tests under the GeneType brand, targeting colorectal and breast cancers. The firm is also engaged in the development of new diagnostic tools aimed at various health conditions, such as cardiovascular disease, type 2 diabetes, prostate cancer, and melanoma. Furthermore, Genetic Technologies provides a comprehensive array of genetic testing services that extend beyond human health to include medical, animal, forensic, and botanical applications. The company actively collaborates with leading institutions, including the University of Melbourne and Memorial Sloan Kettering, to enhance its research capabilities and product offerings. With a workforce of 55 employees, Genetic Technologies Limited continues to position itself as a leader in the molecular diagnostics field, dedicated to improving healthcare outcomes through innovative genetic testing solutions.
What Products and Services Does GNTLF Offer?
- Develop advanced predictive assessment instruments for women's health.
- Offer BREVAGenplus, a risk evaluation test for non-inherited breast cancer.
- Provide cancer risk assessment tests under the GeneType brand.
- Engage in the development of diagnostics for various health conditions.
- Deliver a comprehensive suite of genetic testing services.
- Collaborate with leading research institutions to enhance product offerings.
How Does GNTLF Make Money?
- Generate revenue through the sale of genetic testing products and services.
- Leverage partnerships with healthcare providers to promote risk assessment tools.
- Engage in research collaborations to develop innovative diagnostic solutions.
- Expand product offerings to include a wider range of genetic testing applications.
- Focus on international markets to increase customer base and revenue streams.
What Industry Does GNTLF Operate In?
The molecular diagnostics industry is experiencing robust growth, driven by increasing demand for personalized medicine and advancements in genetic testing technologies. The global market for molecular diagnostics is expected to reach $11.5 billion by 2026, growing at a CAGR of 10.9%. Genetic Technologies Limited positions itself within this expanding market by focusing on women's health and cancer risk assessment, an area that is gaining significant attention from healthcare providers and patients alike. The competitive landscape includes established players in the diagnostics sector, but Genetic Technologies' specialized focus on predictive genetic testing provides a unique niche that differentiates it from larger competitors.
Who Are GNTLF's Key Customers?
- Healthcare professionals including obstetricians, gynecologists, and breast surgeons.
- Breast health clinics and imaging centers seeking reliable risk assessment tools.
- Research institutions collaborating on genetic testing and diagnostics.
- Patients seeking personalized health assessments and genetic testing services.
- Healthcare organizations looking to implement preventative health measures.
F-Score 3/9Financial Health
Genetic Technologies Limited's Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Genetic Technologies Limited (GNTLF) Valuation Context
Valued at $1.34B, GNTLF is classified as a small-cap stock. Relative to its peer group, GNTLF's quantitative score of 44/100 is below the peer average of 58/100.
Company Profile
Genetic Technologies Limited operates in the Medical - Diagnostics & Research industry within the Healthcare sector. It is headquartered in Fitzroy, AU. The company is led by CEO Kevin Camilleri. GNTLF has traded publicly since 2000.
FY2026 estForward Outlook
Wall Street analysts project Genetic Technologies Limited revenue of about $28.6M for fiscal 2026, with EPS near $0.00.
GNTLF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2024
Bull Case vs Bear Case
Bull Case
- Innovative product offerings in predictive genetic testing.
- Strong partnerships with leading research institutions.
- Established market presence in Australia and growing interest in the U.S.
- Upcoming: Expansion of BREVAGenplus into new healthcare markets.
Bear Case
- Current negative profit margin indicating financial challenges.
- Limited brand recognition compared to larger competitors.
- Dependence on a small number of key products for revenue.
- Ongoing: Intense competition from established players in the molecular diagnostics sector.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
GNTLF Latest News
No recent news available for GNTLF.
GNTLF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for GNTLF.
Price Targets
Wall Street price target analysis for GNTLF.
GNTLF MoonshotScore
What does this score mean?
The MoonshotScore rates GNTLF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Kevin Camilleri
CEO
Kevin Camilleri has extensive experience in the healthcare and biotechnology sectors. He has held various leadership positions within the industry, focusing on strategic growth and innovation. His educational background includes degrees in business and life sciences, equipping him with a unique blend of skills to lead Genetic Technologies Limited.
Track Record: Under Kevin's leadership, Genetic Technologies has expanded its product offerings and strengthened its collaborative efforts with research institutions, driving innovation in genetic testing. His strategic vision has positioned the company for growth in the evolving molecular diagnostics landscape.
GNTLF OTC Market Information
The OTC Other tier includes companies that do not meet the requirements for higher tiers like OTCQX or OTCQB, often resulting in lower visibility and liquidity. This tier is typically associated with smaller companies and may have less stringent reporting requirements.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial reporting and transparency compared to companies on major exchanges.
- Higher volatility and liquidity risks associated with OTC trading.
- Potential for lower investor interest and market participation.
- Verify the company's financial health through available reports.
- Assess the competitive landscape and market positioning.
- Evaluate the management team's experience and track record.
- Investigate partnerships and collaborations with research institutions.
- Monitor regulatory developments impacting the healthcare sector.
- Established partnerships with reputable research institutions.
- Presence of a dedicated management team with industry experience.
- Clear focus on innovation and development in genetic testing.
What Investors Ask About Genetic Technologies Limited (GNTLF) — Healthcare
What does Genetic Technologies Limited do?
Genetic Technologies Limited specializes in molecular diagnostics, focusing on predictive genetic testing for women's health. Its flagship product, BREVAGenplus, is a validated risk evaluation test for non-inherited breast cancer. The company also offers additional cancer risk assessments under the GeneType brand and is involved in developing new diagnostics for various health conditions.
What are the main risks for GNTLF?
Genetic Technologies Limited faces several risks, including intense competition from larger players in the molecular diagnostics industry, which could impact market share. Additionally, regulatory challenges may hinder product development and market entry. The company's OTC trading status introduces liquidity and volatility risks that could affect stock performance.
What growth opportunities does Genetic Technologies Limited have in healthcare?
Genetic Technologies Limited has significant growth opportunities, particularly in expanding its flagship product, BREVAGenplus, into new markets. The increasing demand for personalized medicine and preventative healthcare is driving interest in genetic testing. Furthermore, the company's ongoing development of new diagnostic tools for conditions like cardiovascular disease presents additional avenues for revenue growth.
What are the key factors to evaluate for GNTLF?
Genetic Technologies Limited (GNTLF) holds an AI score of 44/100 (low). Not financial advice.
How frequently does GNTLF data refresh on this page?
GNTLF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven GNTLF's recent stock price performance?
Genetic Technologies Limited (GNTLF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative product offerings in predictive genetic testing. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider GNTLF overvalued or undervalued right now?
Valuing Genetic Technologies Limited (GNTLF) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying GNTLF?
Before investing in Genetic Technologies Limited (GNTLF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data may vary due to the OTC trading status and limited reporting requirements.